Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07431086
PHASE2

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

Sponsor: Regeneron Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study will test how safe and effective the study drug works compared to placebo in people who are overweight or obese but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much the study drug is in the blood at different times * How well the study drug works * If your body makes antibodies to the study drug, as this may cause the study drug to not work as well

Official title: A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, Tolerability, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity in the US

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-03-16

Completion Date

2026-12-18

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

DRUG

Olatorepatide

Administered per the protocol

DRUG

Placebo

Administered per the protocol

Locations (1)

Flourish Research - San Antonio Medical Trials

San Antonio, Texas, United States